Top 5 Building Product Stocks To Invest In Right Now

It's been a volatile year for the roofing industry, and over the last three months, investors have seen more downside. Roofing materials distributor Beacon Roofing Supply (NASDAQ: BECN  ) is down 11.5% in the last three months, and building products manufacturer Owens Corning (NYSE: OC  ) fell 5.5% in the same period -- all in a year when many commentators thought this sector would outperform.�

It's complicated
A resurgent housing market should lead to a marginal increase in new residential roofing demand, while the underlying reroofing demand should provide its usual support. Indeed, these conditions looked like they were in place for 2013, and analysts built a fair amount of optimism into their expectations. So what went wrong?

First, the US has had some unusual weather patterns in recent years. In previous years, hurricane Irene (and to a lesser extent Sandy) helped to generate reroofing demand, while this year's weather has been far more clement. Worse yet, according to Owens Corning, those storms pulled forward reroofing work that homeowners might otherwise have planned to do this year. And this spring's bout of wet weather further hurt roofing activity, because contractors simply couldn't work.

Top 10 Oil Stocks To Watch Right Now: Cardica Inc.(CRDC)

Cardica, Inc. engages in the development of an endoscopic microcutter product line for use by thoracic, bariatric, colorectal, and general surgeons primarily in the United States and internationally. Its microcutter product line under development includes Microcutter XPRESS 30, a multi-fire endolinear microcutter device based on the company?s proprietary ?staple-on-a-strip? technology; Microcutter XPRESS 45, a multi-fire endolinear microcutter device with a 45 millimeter staple line; Microcutter XCHANGE 30, a cartridge based microcutter device; Microcutter FLEXCHANGE 30, a cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling; and Microcutter XPRESS 60, a cutting and stapling device for the bariatric and thoracic surgery markets. The company also designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery. It offers C-Port Distal Anas tomosis Systems, such as C-Port xA Anastomosis System to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis System to enable automated anastomoses to be performed as part of coronary artery bypass grafting procedures; C-Port X-CHANGE System, a cartridge-based reloadable C-Port system; and PAS-Port Proximal Anastomosis System to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. Cardica, Inc. sells its products through direct sales force, as well as through independent distributors and manufacturers? representatives. The company was formerly known as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Cardica, Inc. was founded in 1997 and is headquartered in Redwood C ity, California.

Advisors' Opinion:

• [By Bryan Murphy]

  Neither Acorn Energy Inc. (NASDAQ:ACFN) nor Cardica, Inc. (NASDAQ:CRDC) may look all that compelling with just a passing glance. The longer one examines CRDC and ACFN, however - and really gets a grasp of their underlying stories - the more compelling each one becomes. In fact, newcomers may want to go ahead and put both budding stocks on their watchlists, if not in their portfolios.

Top 5 Building Product Stocks To Invest In Right Now: BIND Therapeutics Inc (BIND)

BIND Therapeutics, Inc., incorporated on May 19, 2006, is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).

Accurins represent the evolution of targeted therapies and nanomedicine. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. The four components include Targeting ligands, Stealth and protective layer, Controlled-release polymer matrix and Therapeutic payload. The Company focuses to use its medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, the Company entered into collaboration agreements with several biopharmaceutical companies to develop and commercialize Accurins that are based on its collaborators��therapeutic payloads. The Company�� programs include BIND-014, solid tumor accurin and hematologic cancer accurin.

Advisors' Opinion:

• [By Anna Prior]

  Bind Therapeutics sa(BIND)id a collaboration with Amgen Inc.(AMGN) has been ended after both companies agreed not to pursue an option to jointly develop a molecularly targeted cancer therapy. Bind Therapeutics shares fell 11% to $11.50 premarket.

• [By John Udovich]

  The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:

• [By John Udovich]

  Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.

• [By Garrett Cook]

  BIND Therapeutics (NASDAQ: BIND) was down, falling 10.56 percent to $11.52 after the company reported the closing of collaboration deal with Amgen (NASDAQ: AMGN).

Top 5 Building Product Stocks To Invest In Right Now: KKR Financial Holdings LLC (KFN)

KKR Financial Holdings LLC, incorporated on January 17, 2007, is a specialty finance company focused on a range of asset classes. The Company�� holdings primarily consist of below investment grade syndicated corporate loans, also known as leveraged loans, high yield debt securities, private equity, interests in joint ventures and partnerships, and working and royalty interests in oil and gas properties. It operates in three segments: Credit, Natural resources, and other. The Credit segment includes primarily below investment grade corporate debt comprised of senior secured and unsecured loans, mezzanine loans, private and public equity investments, high yield bonds, and distressed and stressed debt securities. The Natural Resources segment consists of non-operated working and overriding royalty interests in oil and natural gas properties. Natural Resources segment excludes private equity focused on the oil and gas sector. The Other segment includes all other portfolio holdings, including commercial real estate.

The Company�� majority of holdings consist of corporate loans and high yield debt securities held in collateralized loan obligation (CLO) transactions that are structured as on-balance sheet securitizations and are used as long term financing for its investments in corporate debt. The Company is externally managed and advised by KKR Financial Advisors LLC. The Company�� collateralized loan obligation (CLO) consist of seven CLO transactions, KKR Financial CLO 2005-1, Ltd. (CLO 2005-1), KKR Financial CLO 2005-2, Ltd. (CLO 2005-2), KKR Financial CLO 2006-1, Ltd. (CLO 2006-1), KKR Financial CLO 2007-1, Ltd. (CLO 2007-1), KKR Financial CLO 2007-A, Ltd. (CLO 2007-A), KKR Financial CLO 2011-1, Ltd. (CLO 2011-1) and KKR Financial CLO 2012-1, Ltd. (CLO 2012-1) (collectively the Cash Flow CLOs). The Company�� objective is to provide long-term value for its shareholders by generating an attractive total return through cash distributions and increased enterprise value.

Advisors' Opinion:

• [By Lauren Pollock]

  KKR(KKR) & Co. said it reached a deal to acquire KKR Financial Holdings LLC(KFN), bringing under its roof the separate, specialty-finance company managed by the private-equity firm that pursues debt investments and other bets. KKR, known for large debt-fueled corporate takeovers, signed an agreement to take over the sister firm in a $2.6 billion all-stock deal, the New York company said. Shares of KKR Financial jumped 28% to $12.12 in premarket trading.

Top 5 Building Product Stocks To Invest In Right Now: Energen Corporation (EGN)

Energen Corporation, an energy holding company, engages in the development, acquisition, exploration, and production of oil, natural gas, and natural gas liquids in the continental United States. The company is also involved in the purchase, distribution, and sale of natural gas to residential, commercial, and industrial customers, as well as to other end-users of natural gas in central and north Alabama. In addition, it provides gas transportation services to industrial and commercial customers located on its distribution system. As of December 31, 2012, the company had approximately 750 million barrels of oil-equivalent proved, probable, and possible reserves. Energen Corporation was founded in 1929 and is headquartered in Birmingham, Alabama.

Advisors' Opinion:

• [By Marc Bastow]

  Oil and gas energy holding company Energen (EGN) raised its quarterly dividend 3.4% to 15 cents per share, payable on Mar. 3 to shareholder of record as of Feb. 14.
  EGN Dividend Yield: 0.86%

• [By Lauren Pollock]

  Energen Corp.(EGN) said it expects last month’s severe weather in West Texas to weigh on results from the oil-and-gas production company’s Permian Basin operations.

• [By Ben Levisohn]

  Smaller producers appear to agree, with Whiting Petroleum (WLL) noting that its production growth would be unchanged at oil prices of around $75 while an average oil price in the low $80s would not affect Energen�� (EGN) production plans.